The REMAP-CAP trial has reported a finding of survival and time to
recovery benefits for tocilizumab or sarilumab, over and above current standard
of care (including corticosteroids), in the immune modulation therapy domain of
the REMAP-CAP platform trial.
Work is now underway to develop a UK clinical commissioning policy for
tocilizumab and sarilumab, which will be based on a NICE review of the
available research evidence. The policy
will replace the attached Interim Position Statement.
This alert sets out immediate steps which NHS acute trusts / health
boards are asked to take to support treatment of patients admitted to intensive
care with COVID-19.